(Reuters) - Challenges in Pfizer Inc's supply chain for its COVID-19 vaccine played a role in its decision to slash its 2020 production target, the Wall Street Journal reported on Thursday.
Pfizer has said in recent weeks that it anticipates producing 50 million doses of its COVID-19 vaccine this year. That is down from an earlier target of 100 million doses. Pfizer's vaccine relies on a two dose regimen, meaning 50 million doses is enough to inoculate 25 million people.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!